TG Therapeutics Investigational Trial Site

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Recruiting	Not stated	2026-09-23	NCT06433752
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab	Relapsing Multiple Sclerosis	Recruiting	Phase 3	2026-09-21	NCT05877963
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, multiple sclerosis, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, neuromyelitis optica, optic nerve disorder, optic neuritis, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy	Recruiting	Phase 1	2026-09-09	NCT06680037

Clinical trials